CNS Study of Patients Switching From Tacrolimus to Envarsus

• Status: Active, not recruiting
• Trial end date: 2020-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a pilot study documenting the neurotoxic side effects including tremors in patients with a stable graft who are receiving Tacrolimus following kidney transplantation. A standardized questionnaire will be used to document these symptoms.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Colorado, Denver
• Treatments: Tacrolimus

Criteria

Inclusion Criteria:

• Kidney transplant recipients with stable graft function.

• More than 1 months post-transplant.

• 18+ years of age with some CNS problems secondary to Prograf (tacrolimus).

Exclusion Criteria:

• Multi-organ patients (kidney/pancreas, kidney/liver).

• Evidence of graft rejection or treatment of acute rejection within 14 days prior to baseline visit.

• Inability to self-administer the QOL questionnaires.